Chromocell launches eye pain program targeting $2.5B market; hires Dr. Simon Chandler

Pelthos Therapeutics Inc.

NaV1.7 sodium channel program for eye pain; addresses 5M annual U.S. corneal abrasions.
Dr. Simon Chandler hired to lead program; 30+ years ophthalmic drug dev experience (Santen, Allergan).
Program targets acute (corneal abrasion, glaucoma) and chronic (dry eye, neuropathic) indications.
Company believes NaV1.7 platform can treat all eye pain indications, currently under-served.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.